Prostalund AB
7PL0
Company Profile
Business description
Prostalund AB develops, markets and sells urological products. The Company has a treatment concept (CoreTherm Concept) for personalized heat treatment for the condition benign prostatic hyperplasia, also known as BPH or BPE, which mainly affects men over the age of 50. It has developed a new platform, CoreTherm Eagle which includes an inbuilt computer, real-time temperature reading, patient data storage and inbuilt recommendations for treating physicians.
Contact
Scheelevagen 19
LundSE-223 63
SWET: +46 46120908
Sector
Healthcare
Stock type
Defensive
Industry
Medical Care Facilities
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% |
| CAC 40 | 8,145.97 | 11.32 | -0.14% |
| DAX 40 | 24,028.37 | 90.52 | -0.38% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,731.68 | 28.38 | -0.29% |
| HKSE | 25,906.65 | 376.04 | -1.43% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% |
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |